INSIGHTS ON DRUG DEVELOPMENT

• Formulation Strategies For Enabling "Undevelopable" Compounds

  KinetiSol enhances bioavailability of poorly soluble drugs like Vemurafenib by producing dense amorphous dispersions, outperforming traditional MBP methods in pharmacokinetics and dissolution.

• Getting The Most Out Of Cell-Based Assays With The Optimal Read Function

  Gain insight into a whole-well fluorescence analysis that improves sensitivity and reproducibility in cell-based assays by accounting for uneven cell distribution.

• Developing Amorphous Solid Dispersions For Poorly Soluble Drugs

  Discover how a strategic amorphous solid dispersion approach improved bioavailability and advanced a low-solubility compound toward clinical readiness in just four weeks.

• Decoding The Conformational Plasticity Of Ternary Complexes For Protacs' Differential Activity

  Leverage our insights into PROTAC ternary complex plasticity and stability to accelerate the design of next-generation therapeutics.

• Formulation Of Crystalline Nanoparticles Enabling Superior Drug Load

  8/13/2024

  Explore how bioavailability of poorly soluble APIs can be improved and patient compliance enhanced by reducing the size or number of tablets that a patient must take to achieve the required dose.

• Is Mannitol Hemihydrate Detrimental To Protein Stability?

  10/16/2024

  Maintaining an amorphous excipient matrix is crucial for protein stability. Learn about the importance of storage conditions in managing mannitol hemihydrate dehydration and ensuring protein stability.

• Following The Science To Develop Best-In-Class Cancer Drugs

  12/11/2023

  As innovative cancer therapeutics continue to enter the clinical trial pipeline, some developers are shifting their focus toward developing drugs that are safe and efficacious with minimal toxicity.

• Streamlining Biologics Development: Leveraging Small-Scale Studies For Greater Efficiency

  9/25/2025

  Uncover how a data-driven approach to small-scale studies not only accelerates development timelines but also enhances decision-making and resolves full-scale manufacturing challenges across diverse biologic modalities.

• A Holistic Approach To Understanding High And Low HEK293 Producer

  4/4/2025

  Despite advancements in AAV-based gene therapy, key aspects of AAV biology and production remain unclear. Find out how researchers are exploring HEK293 subclones to identify traits that enhance viral vector yields.